Postural orthostatic tachycardia syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Postural orthostatic tachycardia syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Human Normal Immunoglobulin for Adults with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-human-normal-immunoglobulin-for-adults-with-post-covid-19-postural-orthostatic-tachycardia-syndrome-pots/ Wed, 29 Apr 2026 15:04:51 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-human-normal-immunoglobulin-for-adults-with-post-covid-19-postural-orthostatic-tachycardia-syndrome-pots/ This clinical trial is focused on studying a condition known as Postural Orthostatic Tachycardia Syndrome (POTS), which can occur after a COVID-19 infection. POTS is a disorder that affects blood flow, leading to symptoms like dizziness and a rapid increase in heart rate when standing up. The study will evaluate the effectiveness and safety of a treatment called IgPro20, also known as Hizentra, which is a solution for injection containing human normal immunoglobulin. This treatment is compared to a placebo to see if it can help improve the symptoms of post-COVID POTS.

The purpose of the study is to determine if IgPro20 can effectively reduce the symptoms of POTS in adults who have developed this condition after recovering from COVID-19. Participants in the study will receive either the IgPro20 treatment or a placebo. The study will monitor changes in symptoms and any side effects over a period of time. The treatment is administered through a subcutaneous injection, which means it is injected under the skin.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include measuring changes in heart rate and evaluating symptoms related to POTS. The study aims to see if participants no longer meet the diagnostic criteria for POTS after treatment. Additionally, the study will monitor any adverse effects that may occur during the treatment period. The goal is to provide valuable information on the potential benefits of IgPro20 for individuals suffering from post-COVID POTS.

]]>